| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
RLR (RIG-I-like receptor) signaling pathway, targeting factors at or above the level of MAVS (mitochondrial antiviral signaling protein). The compound drives IRF3 (interferon regulatory factor 3) activation. KIN1408 is an antiviral agent with broad-spectrum activity.
|
|---|---|
| ln Vitro |
In THP-1 cells, KIN1408 can activate IRF3, stimulate the production of innate immune genes (MDA5, RIG-1, Mx1, IRF7, and IFIT1), and partially block dengue virus 2 RNA. Additionally, KIN1408 has efficacy against the Lassa virus, Nipah virus, Ebola virus, HCV, and influenza A [1][2].
KIN1408 induces IRF3 nuclear translocation with ECmax = 5 µM in Huh7 cells in 20 hours. It shows no significant cytotoxicity at 50 µM/20 h in Huh7 or 20 µM/36 h in HEK293 cultures. KIN1408 exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses. |
| ln Vivo |
No detailed in vivo activity data has been published in the available literature. KIN1408 is primarily characterized as an in vitro antiviral research tool. Further in vivo studies in animal models of viral infection would be needed to evaluate its antiviral efficacy, pharmacokinetics, and pharmacodynamics in vivo.
|
| Enzyme Assay |
IRF3 nuclear translocation assay: Huh7 cells are seeded in 96-well plates and treated with KIN1408 at varying concentrations (0.1-50 µM) for 20 hours. Cells are fixed, permeabilized, and stained with anti-IRF3 antibody followed by fluorescent secondary antibody. Nuclear translocation of IRF3 is quantified by high-content imaging or fluorescence microscopy. The ECmax (concentration for maximum effect) is determined.
|
| Cell Assay |
Antiviral activity assay: Virus-infected cells (e.g., HCV replicon cells or influenza A-infected cells) are treated with KIN1408 at varying concentrations for 24-72 hours. Viral replication is measured by qRT-PCR for viral RNA, or by plaque assay for infectious virus particle production. Cytotoxicity is assessed using a cell viability assay (e.g., MTT or CellTiter-Glo). EC50 for antiviral activity and CC50 for cytotoxicity are calculated.
|
| Animal Protocol |
No in vivo animal experimental protocols have been published for KIN1408 in the available literature. In vivo studies would typically involve mouse models of viral infection (e.g., influenza A or Ebola virus infection), where KIN1408 would be administered via oral, intraperitoneal, or intravenous routes, followed by measurement of viral load, survival rate, and immune response markers.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data has been published in the available literature. KIN1408 has a molecular weight of 479.50 g/mol and molecular formula C₂₅H₁₉F₂N₃O₃S. Comprehensive PK parameters such as bioavailability, half-life, and plasma protein binding remain to be characterized.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published in the available literature. KIN1408 shows no significant cytotoxicity at 50 µM in Huh7 cells or 20 µM in HEK293 cultures. Standard laboratory safety practices should be followed when handling this compound. Further toxicological studies would be needed for therapeutic development.
|
| References | |
| Additional Infomation |
KIN1408 is a RLR agonist that activates the RIG-I-like receptor signaling pathway at or above the level of MAVS, driving IRF3 activation. It has broad-spectrum antiviral activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses. KIN1408 induces IRF3 nuclear translocation with an ECmax of 5 µM without significant cytotoxicity. No clinical trials or approved上市 status have been reported.
|
| Molecular Formula |
C25H19F2N3O3S
|
|---|---|
| Molecular Weight |
479.498471498489
|
| Exact Mass |
479.111
|
| CAS # |
1903800-11-2
|
| PubChem CID |
119081414
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
6.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
657
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C2C=CC(=CC=2N=C1NC(C1C=CC(=CC=1)OC(F)F)C1C=CC2=CC=CN=C2C=1O)OC
|
| InChi Key |
YSGBFDHVEQJPPX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H19F2N3O3S/c1-32-17-9-11-20-19(13-17)29-25(34-20)30-21(15-4-7-16(8-5-15)33-24(26)27)18-10-6-14-3-2-12-28-22(14)23(18)31/h2-13,21,24,31H,1H3,(H,29,30)
|
| Chemical Name |
7-[[4-(difluoromethoxy)phenyl]-[(5-methoxy-1,3-benzothiazol-2-yl)amino]methyl]quinolin-8-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 39 mg/mL (~81.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0855 mL | 10.4275 mL | 20.8551 mL | |
| 5 mM | 0.4171 mL | 2.0855 mL | 4.1710 mL | |
| 10 mM | 0.2086 mL | 1.0428 mL | 2.0855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
